Virgin Galactic is stuck between a finished development program and a spaceline that has not yet restarted commercial service. Management moved first commercial flight from late this year into February of next year so avionics and systems installations can finish. That slip is the quarter's real event. Demand is not the missing piece. A limited expedition tranche priced at $750,000 booked out ahead of schedule and added more than $50 million of expected future spaceflight revenue. The investment debate is whether the next-generation fleet reaches a repeatable cadence before liquidity and a completed equity program force another dilutive raise.
The income statement barely moves the story. Second-quarter revenue was $134 thousand and came from astronaut access fees rather than flown missions. Cash, cash equivalents, and marketable securities stood at $286 million after an at-the-market equity program, a tap that sells stock into the open market over time, that raised $134 million. Those two figures describe a company that is still funding a factory, not harvesting a fleet. GAAP operating expenses eased to $65 million while research spending collapsed and spaceline operations nearly doubled, which is the mix shift of a program leaving design and entering build-and-test. Adjusted earnings before interest, taxes, depreciation, and amortization, a cash-earnings proxy that strips stock pay, legal settlement, and the debt-extinguishment gain, stayed near a $52 million quarterly loss. Free cash outflow of $91 million, operating cash minus capital spending, improved from the year-ago period but still consumes a large slice of the mid-year cash stack each quarter.
The cash math is now tighter than the demand story. Management guides third-quarter free cash outflow between $95 million and $100 million. Fourth-quarter outflow is guided to a range of $80 million to $90 million. The at-the-market program is substantially complete after selling most of a $300 million authorization. Management itself concludes that conditions raise substantial doubt about the company's ability to continue as a going concern. The next year therefore turns on three observables: an October captive-carry test, a February commercial restart, and whether another equity or structured financing appears before those dates.